Related Experiment Video
Updated: Feb 26, 2026

Establishment of an Experimental Mouse Model of Endometrioma to Study its Related Infertility
Published on: April 5, 2024
An Overview of Endometriosis and Potential Pharmacogenetic Targets
Noelia Pérez-Gómez1,2, María Ángeles Martínez-Zamora3, Francisco Carmona3
1Research Unit, Fundación Burgos Por La Investigación de La Salud (FBIS), Hospital Universitario de Burgos, Burgos, 09006, Spain.
Background:
Endometriosis is a chronic inflammatory disease characterized by the presence of endometrial-like tissue outside the uterine cavity. It affects approximately 10-15% of women of reproductive age globally and is characterized by heterogeneous symptoms with chronic pelvic pain, dysmenorrhea, and infertility being the most common. Although pharmacological treatments are available to manage its symptoms, many women either do not respond to these therapies or experience adverse drug reactions (ADRs) that outweigh the original symptoms of endometriosis.
Rationale/Objectives:
The aim of this review is to provide a comprehensive overview of endometriosis and to identify pharmacogenetic markers that might influence drug response in its treatment and management.
Outcomes:
Current research highlights a critical gap in pharmacogenetic biomarkers for endometriosis treatment, limiting the potential for personalized therapeutic strategies.
Wider Implications:
Integrative multi-omics approaches combining genetic, inflammatory, and hormonal profiles may enhance patient stratification and optimize individualized care.
Related Concept Videos
Pharmacogenomics: Identification of New Drug Targets
Pharmacogenetics and Pharmacogenomics: Overview
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Pharmacogenetics of Drug Metabolism: Overview
Principles of Pharmacogenetics: Types of Genetic Variants

